Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Work In Process: 2022-2023

Historic Work In Process for Kiniksa Pharmaceuticals International (KNSA) over the last 2 years, with Dec 2023 value amounting to $18.3 million.

  • Kiniksa Pharmaceuticals International's Work In Process rose 189.26% to $18.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $18.3 million, marking a year-over-year increase of 189.26%. This contributed to the annual value of $18.3 million for FY2023, which is 189.26% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Work In Process of $18.3 million as of FY2023, which was up 189.26% from $6.3 million recorded in FY2022.
  • Kiniksa Pharmaceuticals International's Work In Process' 5-year high stood at $18.3 million during FY2023, with a 5-year trough of $6.3 million in FY2022.
  • Its 2-year average for Work In Process is $12.3 million, with a median of $12.3 million in 2022.
  • Data for Kiniksa Pharmaceuticals International's Work In Process shows a peak YoY spiked of 189.26% (in 2023) over the last 5 years.
  • Over the past 2 years, Kiniksa Pharmaceuticals International's Work In Process (Yearly) stood at $6.3 million in 2022, then spiked by 189.26% to $18.3 million in 2023.